glp 1 for perimenopause weight gain During Menopause: Solutions in the Era of GLP1-agonists Menopause Weight Gain & GLP-1

These innovations aim to offer more potent and durable clinical outcomes, improve patient responsiveness and address the growing need for advanced therapies within the global obesity landscape

The results of phase 2 (dose-ranging) trials with primary endpoints of HbA 1c change (Rosenstock et al, 2023) and body-weight change (Jastreboff et al, 2023) are shown in Table 6

Gastrointestinal Issues GI side effects are the most common, especially early on: Nausea Vomiting Diarrhea Constipation These may lessen over time but can persist in some patients, leading to dehydration and nutritional deficiencies

it's a new therapeutic approach targeting interconnected metabolic dysfunction at its core